⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Z Prime Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Z Prime Therapeutics
↗Unknown, USA
Z Prime Therapeutics is a biotechnology company focused on developing first-in-class oncology therapeutics using an innovative RNA degradation mechanism. The company targets key enzymes that regulate mRNA stability to address challenging, transcription-addicted cancers, such as those driven by MYC dysregulation.
By utilizing synthetic lethality principles, Z Prime aims to provide effective therapies for cancers that currently lack viable treatment options. The company is currently in the discovery phase, advancing its pipeline from hit identification to lead optimization.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$10.4M
PIPELINE
Stage:Discovery
Lead Drug Stage:Hit-to-Lead
Modalities:Small molecule, RNA degradation
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LINKS
Website:zprimetx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Z Prime Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.